Illinois-based Surgisphere Corporation had a brief moment in the limelight this year following its infamous study of hydroxychloroquine. But the impact of the company’s deception reverberated across world.

The high-profile retractions of two COVID-19 studies stunned the scientific community earlier this year and prompted calls for reviews of how science is conducted, published, and acted upon. The warning signs had been there all along.

The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.

Fast science—with all its warts—is making unprecedented progress in the fight against COVID-19.

All authors other than company founder and CEO Sapan Desai were “unable to complete an independent audit of the data,” The Lancet states.

Early career researchers face unique challenges when a senior collaborator becomes embroiled in allegations of scientific malpractice.

After the initial announcements of two retractions, scientists have mobilized to interrogate the data in nearly 150 of Jonathan Pruitt’s papers.

Papers from Catherine Verfaillie’s lab have been drawing fire for years.

Criticism of the paper first surfaced in 1994, and its author was accused of scientific misconduct.